BISOPROLOL IN PATIENTS WITH CORONARY HEART DISEASE, ARTERIAL HYPERTENSI0N, AND CONCOMITANT PSORIASIS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Beta-blockers (BB) are known to be effectively reduce mortality and the risk of myocardial infarction, stroke, and other cardiovascular events in patients with coronary heart disease (CHD), chronic heart failure, arterial hypertension (AH), and arrhythmias. However, the use of nonselective and secondary generation relatively selectivite BB can be complicated by psoriasis exacerbation or psoriasiform erythema developement, an adverse reaction generally related to the undesirable β 2-adrenoreceptor blockade. One hundred and two hypertensive patients with severe exacerbated psoriasis and CHD were enrolled in the trial aimed to asses efficacy and safety of highly selective b1-blockerbisoprolol (Bidop, Gedeon Richter). The study results showed that bisoprolol while significantly reduced number of anginal attacks and lowered blood pressure, did not affect the psoriasis course and symptom improvement.

全文:

受限制的访问

作者简介

A. Shevchenko

Russian National Research Medical University, Moscow

Email: clin_cardio@yahoo.com

E. Dvoryankova

Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow

Email: clin_cardio@yahoo.com

О. Shevchenko

Russian National Research Medical University, Moscow

Email: clin_cardio@yahoo.com

Yu. Shilova

Dermatovenereology Dispensary Fifteen, Moscow

Email: clin_cardio@yahoo.com

L. Ginzburg

Regional Hospital One, Lyubertsy

Email: clin_cardio@yahoo.com

参考

  1. National Psoriasis Foundation. Psoriasis statistics. Доступно в сети Интернет по адресу: http://www.psoriasis.org / Последнее обращение: 22.01.2012.
  2. Kimball A., Gladman D., Gelfand J. et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening // J. Am. Acad. Dermatol. - 2008; 58: 1031-1042.
  3. Mallbris L., Akre О., Granath F.etal. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients // Eur.J. Epidemiol. - 2004; 19 (3): 225-230.
  4. Kim G., Del Rosso J. Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? Understanding Pathophysiology and Clinical Relevance // J. Clin. Aesthet. Dermatol. - 2010; 3(1): 32-38.
  5. Mobacken H. Cutaneous sideefects from beta-blockers and other antihypertensive agents // Acta Med. Scand. - 1979; 628: 77-80.
  6. Hodl S. Nebenwirkungender Beta-Rezeptorenblocker and erhaut // Z. Hautkr. - 1983; 58: 17-28.
  7. Lionel F., Baker B. Triggering psoriasis: the role of infections and medications // Clin. Dermatol. - 2007; 25: 606-615.
  8. Tsankov N., Irena A., Kasandjieva J. Drug-induced psoriasis: recognition and management // Am.J. Clin. Dermatol. - 2000; 1: 159-165.
  9. Heng M., Heng M. Beta-adrenoceptor antagonist-induced psoriasiform eruption Clinical and pathogenetic aspects // Int.J. Dermatol. - 1988.279619-627.
  10. Buhring K., Sailer H., Faro H. et al. Pharmacokinetics and metabolism of bisoprolol-14C in threeanimal species and in humans // J. Cardiovasc. Pharmacol. - 1986; 8 (11): 21-28
  11. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid // Dermatologica. - 1978; 157: 238-244.
  12. Адаскевич В.П. Диагностические индексы в дерматологии, - М.: Медицинская книга, 2004: 107-108.
  13. Gelfand J., Feldman S., Stern Retal. Determinant of quality of life in patients with psoriasis: a study from the US population // J. Am. Acad. Dermatol. - 2004; 51: 704-708.
  14. Белугина 0., Яговдик H., Белугина И. Тревожность, депрессия и качество жизни у больных псориазом. Тезисы З. НПК «Санкт-Петербургские дерматологические чтения», - СПб., 2009.
  15. Шевченко О.П., Дворянкова Е.В., Шевченко А.О. Статины у больных хроническими воспалительными заболеваниями кожи: эффективность, безопасность, перспективы клинического применения // Consilium Medicum. - 2010; 5: 135-140.
  16. Шевченко О.П., Мишнев О.Д., Шевченко А.О. и др. Ишемическая болезнь сердца, - М.; Реафарм, 2005// Патологоанатомическая характеристика легкоранимой атеросклеротической бляшки и методы ее визуализации // Мед. визуализа-ЦИЯ. - 2006; 2: 111-117.
  17. Piertzak A., Zalewska A., Chodorwska G. et al. Cytokines and anticytokines in psoriasis // Clin. Chim. Acta. - 2008; 394: 7-21.
  18. Ackerman A. Histologic Diagnosis of Inflammatory Skin Disease. Philadelphia, Pa: Lea and Febiger; 1978. A method of pattern analysis. - P. 124-126.
  19. Steinkraus V., Steinfath M., Mensing H. Beta-adrenergic blocking drugs and psoriasis // J. Am. Acad. Dermatol. - 1992; 27: 266-267.
  20. Assem E., Banks R. Practolol induced drug eruptions // Proc.R. Soc. Med. - 1973;66: 179-181.
  21. Halevy S., Livni E. Beta-adrenergic blocking drugs and psoriasis: the role of an immunologic mechanism // J. Am. Acad. Dermatol. - 1993; 29 (3): 504-505.
  22. Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism // Diabetes Care. - 1991; 14: 203-209.
  23. Maack C. et al. Characterization of b1-selectivity, adrenoceptor-Gs-protein interaction and inverse agonism of nebivolol in human myocardium // British J. Pharmacology. - 2001; 132: 1817-1826.
  24. Шевченко A.O., Шевченко О.П. Бета-адреноблокаторы. От класс-эффекта к уникальности отдельных представлений // Врач, - 2010; 3: 62-65.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2012
##common.cookie##